Advisor appointed as SKN ramps up acquisition strategy

|

Published 06-MAR-2018 12:41 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Australian natural skin care company Skin Elements Limited (ASX:SKN) has today announced the appointment of corporate advisory firm MMR Corporate Services Pty Ltd as corporate advisors to drive its acquisition strategy in the global natural skin care market.

SKN will be engaging MMR Corporate to act as corporate advisors and transaction facilitators as the company looks to accelerate the acquisition component of its growth model.

As part of the agreement, MRR will advise SKN on capital raising strategies, access to funding facilities, and any required support surrounding a possible transaction.

Under the engagement, MMR will closely work with SKN’s team, in particular the Executive Chairperson Peter Malone, to source and execute high-value merger and acquisition opportunities. The scope for SKN spans companies in Australia and other parts of the world operating in skincare, cosmetics or related sectors.

It’s worth noting here that SKN is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

With several products on the market spanning organic sunscreen, natural skincare treatments, and an all-natural cosmetics product range in the pipeline, SKN is focused on becoming a recognised international leader in the field and rapidly growing its market reach.

Specifically, its growth model is based on delivering sustained sales growth, entering new markets, developing its pipeline products and acquiring complementary, value-accretive companies. In May last year SKN executed its acquisition plans, successfully purchasing McArthur Skincare.

It is now in discussions with groups in south-east Asia and the Middle East in relation to potential acquisition, joint venture and distribution agreements related to skincare products. In addition to helping SKN secure transactions, MMR will also assist in maximising the commercial benefits of any acquisition. The company will release ongoing updates on any future developments to come out of these discussions.

Skin Elements Executive Chairperson Peter Malone said: “Skin Elements has been impressed with the results MMR Corporate has delivered in successfully sourcing capital and developing new business opportunities for emerging Australian growth companies.

“Their track record and capacity in this area is attractive, and we look forward to working closely with the MMR Corporate team to deliver successful acquisition outcomes for the benefit of the Company and our shareholders.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X